fotemustine (Muphoran)

06/01/2008 - "This study aimed to elucidate the potential inner-ear effects of fotemustine, a chemotherapeutic agent which crosses the blood-brain barrier and is used in the treatment of primary and metastatic brain tumours and metastatic melanoma. "
04/01/2001 - "In our study, we investigated the molecular mechanism of acquired resistance of melanoma cells (MeWo) to the chloroethylating drug fotemustine. "
03/01/1996 - "In this study, the authors identified seven-year survivors after completion of the French multicenter Phase II trial of fotemustine for the treatment of metastatic malignant melanoma. "
01/01/1994 - "Phase II trial of fotemustine in patients with metastatic malignant melanoma."
12/01/1992 - "The thiolate-active site of RR from melanoma was inhibited by the new nitrosourea anti-tumour drug fotemustine (IC50 = 10(-4) M as determined from a dose-response study).(ABSTRACT TRUNCATED AT 250 WORDS)"

12/01/1992 - "It seems that fotemustine is superior to any other drug currently available in the treatment of these metastases."
01/01/1998 - "Phase I pharmacological study of intra-arterially infused fotemustine for colorectal liver metastases."
03/01/2014 - "We investigated prospectively the efficacy and toxicity of hepatic intra-arterial (HIA) versus systemic (IV) fotemustine in patients with liver metastases from UM. "
10/01/2002 - "Fotemustine is a nitrosourea that produced similar activity in CNS metastasis as in systemic disease, with a response rate of about 25%. "
01/01/1992 - "The first-pass liver-extraction ratio of fotemustine given as a 4-h HIA infusion, which ranged from 0.4 to 0.9 as estimated in patients receiving i.v. and HIA infusions in a cross-over study, argues for further investigation of HIA foetemustine infusion for the treatment of liver metastases so as to increase the response rate and decrease the occurrence of major toxic side effects in such patients."

01/01/2019 - "Conclusion: The alternative fotemustine administration schedule was an effective and safe treatment for recurrent glioblastoma in elderly patients."
08/01/2016 - "In this study, we assessed the efficacy and safety of fotemustine (FTM) in HGG [fundamentally, glioblastomas (GB)], independent of time of recurrence or performance status. "
05/01/2011 - "In the present study we investigated the feasibility and effectiveness of a new biweekly schedule of fotemustine (FTM) in patients with recurrent glioblastoma, after at least one previous treatment. "
01/01/2019 - "Patients & methods: Patients aged >65 years with recurrent glioblastoma received fotemustine (80 mg/m2; days 1, 15, 30, 45 and 60, and subsequently every 4 weeks). "
01/01/2019 - "Aim: To assess the efficacy and safety of alternative fotemustine administration schedule in elderly patients with recurrent glioblastoma. "

03/01/1999 - "Therefore, fotemustine seems to represent an interesting well-tolerated treatment possibility in patients with inoperable recurrent malignant gliomas of the brain."
01/01/2014 - "We reviewed the most important studies on fotemustine treatment in glioma patients analyzing its pharmacological profile and its activity and safety. "
11/01/2010 - "Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study."
04/01/2001 - "This combined regimen of PCZ and fotemustine was well tolerated with a good disease control rate in heavily pretreated glioma patients and merits further investigation in phase II studies."
03/01/1995 - "Fotemustine in patients with relapsing malignant gliomas - a phase-ii trial."

09/15/2002 - "Phase I study of fotemustine in pediatric patients with refractory brain tumors."
11/01/2011 - "Lecture: fotemustine in brain tumors."
09/15/2002 - "Fotemustine administered at a dose of 150 mg/m(2) every 3 weeks is well tolerated in children and has antitumor activity in several brain tumors. "
01/01/1997 - "A brief comment is made on a new drug, fotemustine, that has an effect on brain metastases. "
01/01/2021 - "We report the primary analysis and 4-year follow-up of the NIBIT-M2 study, the first phase III trial comparing these regimens with fotemustine in patients with melanoma with brain metastases. "